NAD+ Booster NMNH Proved for Safety and Efficacy

Overview

NAD-Booster-NMNH-Proved-for-Safety-and-Efficacy.jpg

NMNH, short for Reduced Beta-Nicotinamide Mononucleotide, refers to the reduced form of NMN. Preclinical studies show that NMNH demonstrates a remarkable 10X surge in NAD+ levels.

EffePharm's UthPeak™ NMNH has completed toxicology and efficacy tests, affirming its safety and health potential in the dietary supplement market. Our animal tests highlight its anti-aging, anti-fatigue, and cardiovascular health benefits. Clinical trials on humans are currently underway. Partnering with Double Wood, the first UthPeak™ NMNH product has launched on Amazon. Download the flyer below to learn more.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Related Topics

IngredientsHealth

Latest Content

Related Resources

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

Paid for by Effepharm Ltd

White Paper

On 11th May 2026, EFSA officially published a positive scientific opinion on EffePharm’s β-NMN as a novel food. This is the first-ever EU official safety endorsement for NMN. UTHEVER® is the 1st NMN ingredient brand to receive EFSA’s positive opinion.

Uthever® NMN: Novel Food Approval Nearing Final Stage

Uthever® NMN: Novel Food Approval Nearing Final Stage

Paid for by Effepharm Ltd

White Paper

One Step Away from EU Market Compliance for NMN. The official positive opinion of Novel Food is expected to be published shortly, which means Uthever® NMN will be the first compliant ingredient.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.